TSY-0110 - Kadcyla (T-DM1) Biosimilar

Model: TSY-0110

Exhibitor: FORMOSA PHARMACEUTICALS , INC

Booth No: N/A

Characteristic

√ TSY-0110 is a biosimilar of the antibody-drug conjugate (ADC) Kadcyla® (ado-trastuzumab emtansine), the first approved ADC therapy for treating HER2-positive early-stage and metastatic breast cancer.
√ Originally developed and globally marketed by Roche and Genentech, Kadcyla® generated approximately USD 2.2 billion in global sales in 2024. TSY-0110 is currently the only known Kadcyla® biosimilar in development specifically targeting the U.S. and European markets.
√ TSY-0110 is in the late preclinical development stage. Formosa Pharma is actively seeking regional or global licensing partners interested in co-developing or commercializing this promising biosimilar asset.